# Missouri AG Sues CBD American Shaman Over Kratom Products – KFVS12 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/missouri-attorney-general-sues-cbd-american-shaman-kratom/ > **Published:** 2026-04-01T06:03:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:33:09-04:00 > **Clinical Summary:** Missouri Attorney General sues CBD American Shaman over kratom products, highlighting regulatory and patient safety concerns in CBD and kratom retail. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic KratomCbdRegulatoryPatient SafetyRetail Why This Matters This case highlights the persistent regulatory gaps between CBD retail operations and kratom distribution, creating patient safety concerns when these substances are co-marketed without appropriate clinical oversight. The legal action underscores the importance of clear product labeling and [consumer protection](https://cedclinic.com/cannabis-mold-contamination-risks-safety-tips/) in cannabis-adjacent retail environments. Clinical Summary Missouri’s Attorney General has filed suit against CBD American Shaman regarding their kratom product sales, though specific allegations are not detailed in the available summary. This represents ongoing regulatory enforcement in the cannabis-adjacent retail space, where CBD retailers often carry multiple botanical products with varying legal and safety profiles. Kratom (Mitragyna speciosa) operates under different regulatory frameworks than CBD and carries distinct pharmacological risks including dependency potential and drug interactions. Dr. Caplan’s Take “When patients tell me they’re shopping at CBD stores, I always ask what else they’re purchasing there. The co-location of CBD and kratom creates confusion about safety profiles that can put patients at risk.” Clinical Perspective 🧠 Clinicians should specifically inquire about all products purchased from CBD retailers, not just cannabis-derived items. Patients may not distinguish between the regulatory status or safety profiles of different botanicals sold in the same location. This case reinforces the need for patients to source cannabis products from licensed dispensaries where possible, rather than retail environments with mixed product lines. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Missouri%20AG%20sues%20CBD%20American%20Shaman%20over%20kratom%20products%20-%20KFVS12%20%40drcaplan&url=https%3A//www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Missouri%20AG%20sues%20CBD%20American%20Shaman%20over%20kratom%20products%20-%20KFVS12%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/](https://www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis-related update?](#What_is_the_clinical_relevance_rating_for_this_cannabis-related_update) - [What substances are covered in this regulatory update?](#What_substances_are_covered_in_this_regulatory_update) - [Why is this considered a patient safety issue?](#Why_is_this_considered_a_patient_safety_issue) - [What type of regulatory changes are being discussed?](#What_type_of_regulatory_changes_are_being_discussed) - [Who should pay attention to these developments?](#Who_should_pay_attention_to_these_developments) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis-related update? This update has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that warrant close monitoring by healthcare professionals. #### What substances are covered in this regulatory update? The update covers both kratom and CBD, focusing on regulatory developments affecting these substances. Both compounds are of interest due to their therapeutic potential and evolving legal status. #### Why is this considered a patient safety issue? Patient safety concerns likely relate to the regulatory uncertainty surrounding kratom and [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). Without clear guidelines, patients may face risks from unregulated products or lack of standardized dosing information. #### What type of regulatory changes are being discussed? While specific details aren’t provided in the summary, this appears to involve emerging policy developments related to kratom and CBD regulation. These changes could affect product availability, quality standards, or prescribing guidelines. #### Who should pay attention to these developments? Healthcare providers, particularly those in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) or [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/), should monitor these developments closely. The “Notable Clinical Interest” rating indicates these changes could impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Missouri AG sues CBD American Shaman over kratom products – KFVS12”, “url”: “https://www.kfvs12.com/2026/04/01/missouri-ag-sues-cbd-american-shaman-over-kratom-products/”, “datePublished”: “2026-04-01T04:05:32Z”, “about”: “missouri ag sues cbd american shaman”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Missouri attorney general sues CBD American Shaman over kratom products – KY3](https://cedclinic.com/missouri-attorney-general-sues-american-shaman-kratom-products/) Detailed coverage of the Missouri Attorney General's lawsuit against CBD American Shaman concerning kratom product sales and regulatory issues. [Read More](https://cedclinic.com/missouri-attorney-general-sues-american-shaman-kratom-products/) [Missouri attorney general sues American Shaman to stop sale of kratom, 7-OH products](https://cedclinic.com/kratom-regulatory-challenges-missouri-legal-action/) Insight into the legal actions taken to halt the sale of kratom and related products by American Shaman in Missouri. [Explore Details](https://cedclinic.com/kratom-regulatory-challenges-missouri-legal-action/) [A South Jersey man sued CBD Kratom stores over his addiction to kratom beverages – MSN](https://cedclinic.com/kratom-addiction-liability-south-jersey-man-lawsuit/) A case study highlighting legal challenges related to kratom addiction and CBD kratom retail practices. [Learn More](https://cedclinic.com/kratom-addiction-liability-south-jersey-man-lawsuit/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).